To initiate the production, Zydus Nycomed will manufacture Pantoprazole, Urapidil and Lornoxicam. Further, the company will produce eight additional APIs by 2011.
Zydus Nycomed claims that the plant earlier provided high quality Key Starting Materials (KSMs) for manufacturing Pantoprazole.
Besides other APIs, the expanded facility will now manufacture the active ingredient of Pantoprazole, Nycomed’s key product for acid-related gastrointestinal diseases.
Zydus Cadila chairman and managing director Pankaj Patel said that the expansion of operations adds newer dimensions to this partnership and opens up new paths to excellence and growth.
Nycomed CEO Hakan Bjorklund said that the plant opening is a significant step forward to getting high quality APIs in Nycomed’s branded generic portfolio produced at competitive costs.
“Having a time-tested and solid partnership in place, like we have with Zydus Cadila, gives me confidence we will continue to achieve our goal of getting medicines that matter to those who need them,” Bjorklund said.
Zydus Nycomed is the joint venture company of Zydus Cadila and Nycomed.